Maternal Microchimerism and Neonatal Tolerance

母体微嵌合和新生儿耐受性

基本信息

  • 批准号:
    8079189
  • 负责人:
  • 金额:
    $ 10.74万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-07-12 至 2011-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The pregnant uterus is an immunologically privileged site. Despite major histocompatibility complex (MHC) and minor H differences, rejection of the fetus by mother is rare and acceptance of migrant maternal cells by the offspring is common. We recently showed a strong neonatal tolerance effect of maternal antigen exposure in mice. This effect, which required both gestation and lactation-phase exposure, resulted in acceptance of maternal antigen + heart allograft for >100 days in 40-50% of recipients, without chronic rejection. The goal of the proposed work will be to test the hypothesis that maternal microchimerism arising by transplacental migration of maternal stem cells and sustained by oral exposure to maternal antigens in the neonate, induces allotolerance while reinforcing self antigen-specific tolerance. This hypothesis will be tested by means of three specific aims: 1) We will determine the influence of maternal exposure upon the development and phenotype of maternal antigen specific T regulatory and T effector cells in an F1 backcross breeding model that results in transplant tolerance to maternal antigens; 2) We will examine the strain differences in mouse F1 back-cross breeding models that exhibit either tolerance or rejection of heart allografts carrying the non-inherited maternal antigens; in particular we will analyze the role of maternal hematopoeitic microchimerism in sustaining neonatally induced tolerance or sensitization in the adult, the extent of parenchyma! cell microchimerism, and the role of intercellular membrane transfer associated with dendritic cells of the offspring; and 3) We will investigate the peculiar resistance of the long-term surviving, maternal antigen + heart allograft to chronic rejection by testing the hypothesis that maternal microchimerism induces T regulatory cells that can suppress autoimmunity to cardiac myosin in susceptible mouse strains. SUMMARY: We believe that if successful, this proposal will advance our understanding of the mechanism(s) of neonatal tolerance to maternal antigens, an area of great significance for the health of mother and baby, especially in autoimmune disease-susceptible individuals. It will also provide fundamental new insights in the field of allo-tolerance, the "holy grail" of transplant immunology.
描述(由申请人提供):怀孕子宫是免疫特权部位。尽管存在主要组织相容性复合体 (MHC) 和次要 H 差异,但胎儿被母亲排斥的情况很少见,而后代接受迁移母体细胞的情况很常见。我们最近在小鼠中展示了母体抗原暴露对新生儿的强烈耐受作用。这种效应需要妊娠期和哺乳期暴露,导致 40-50% 的受者接受母体抗原+同种异体心脏移植超过 100 天,而没有慢性排斥。拟议工作的目标将是检验以下假设:母体微嵌合现象是由母体干细胞经胎盘迁移引起的,并通过口服暴露于新生儿的母体抗原而维持,诱导同种异体耐受,同时增强自身抗原特异性耐受。该假设将通过三个具体目标进行检验:1)我们将确定母体暴露对 F1 回交育种模型中母体抗原特异性 T 调节细胞和 T 效应细胞的发育和表型的影响,该模型导致对母体抗原的移植耐受; 2) 我们将检查小鼠 F1 回交育种模型中的品系差异,这些模型对携带非遗传性母体抗原的同种异体心脏移植物表现出耐受或排斥;特别是,我们将分析母体造血微嵌合体在维持新生儿诱导的耐受或成人致敏的作用,实质范围!细胞微嵌合,以及与后代树突状细胞相关的细胞间膜转移的作用; 3) 我们将通过测试母体微嵌合诱导 T 调节细胞抑制易感小鼠品系对心肌肌球蛋白自身免疫的假设,研究长期存活的母体抗原 + 心脏同种异体移植物对慢性排斥反应的特殊抵抗力。摘要:我们相信,如果成功,该提案将增进我们对新生儿对母体抗原耐受机制的理解,这对于母亲和婴儿的健康具有重要意义,特别是对于自身免疫性疾病易感个体。它还将为同种异体耐受(移植免疫学的“圣杯”)领域提供根本性的新见解。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

William J Burlingham其他文献

William J Burlingham的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('William J Burlingham', 18)}}的其他基金

Natural vs. Pathogenic Th17 responses to col Va1, Ka1tubulin and vimentin
自然与致病性 Th17 对 col Va1、Ka1tubulin 和波形蛋白的反应
  • 批准号:
    9107128
  • 财政年份:
    2016
  • 资助金额:
    $ 10.74万
  • 项目类别:
Collagen a 1 (v) Epitope-Specific TH17 Cells in Heart and Lung Transplantation
心脏和肺移植中的胶原蛋白 a 1 (v) 表位特异性 TH17 细胞
  • 批准号:
    7810369
  • 财政年份:
    2010
  • 资助金额:
    $ 10.74万
  • 项目类别:
Maternal Microchimerism and Neonatal Tolerance
母体微嵌合和新生儿耐受性
  • 批准号:
    8070828
  • 财政年份:
    2010
  • 资助金额:
    $ 10.74万
  • 项目类别:
Minor H Antigen Regulatory Networks as an Alternative to Calcineurin Inhibitors i
次要 H 抗原调节网络作为钙调神经磷酸酶抑制剂的替代品 i
  • 批准号:
    7483662
  • 财政年份:
    2007
  • 资助金额:
    $ 10.74万
  • 项目类别:
Minor H Antigen Regulatory Networks as an Alternative to Calcineurin Inhibitors i
次要 H 抗原调节网络作为钙调神经磷酸酶抑制剂的替代品 i
  • 批准号:
    7305369
  • 财政年份:
    2007
  • 资助金额:
    $ 10.74万
  • 项目类别:
Maternal Microchimerism and Neonatal Tolerance
母体微嵌合和新生儿耐受性
  • 批准号:
    8372382
  • 财政年份:
    2006
  • 资助金额:
    $ 10.74万
  • 项目类别:
Maternal Microchimerism and Neonatal Tolerance
母体微嵌合和新生儿耐受性
  • 批准号:
    9011496
  • 财政年份:
    2006
  • 资助金额:
    $ 10.74万
  • 项目类别:
Maternal Microchimerism and Neonatal Tolerance
母体微嵌合和新生儿耐受性
  • 批准号:
    7447830
  • 财政年份:
    2006
  • 资助金额:
    $ 10.74万
  • 项目类别:
Maternal Microchimerism and Neonatal Tolerance
母体微嵌合和新生儿耐受性
  • 批准号:
    9032622
  • 财政年份:
    2006
  • 资助金额:
    $ 10.74万
  • 项目类别:
Maternal Microchimerism and Neonatal Tolerance
母体微嵌合和新生儿耐受性
  • 批准号:
    8241412
  • 财政年份:
    2006
  • 资助金额:
    $ 10.74万
  • 项目类别:

相似海外基金

Operational tolerance induction by alloantigen-induced Treg cell therapy in rat lung transplantation
同种异体抗原诱导的 Treg 细胞疗法在大鼠肺移植中诱导操作耐受
  • 批准号:
    23K08289
  • 财政年份:
    2023
  • 资助金额:
    $ 10.74万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Selective induction of alloantigen-specific humoral tolerance by MHC-Fc fusion proteins
MHC-Fc 融合蛋白选择性诱导同种异体抗原特异性体液耐受
  • 批准号:
    10432434
  • 财政年份:
    2022
  • 资助金额:
    $ 10.74万
  • 项目类别:
Requirements and mechanisms of alloantigen-induced cardiac allograft survival by cDC1s
cDC1同种异体抗原诱导心脏同种异体移植物存活的要求和机制
  • 批准号:
    10744193
  • 财政年份:
    2022
  • 资助金额:
    $ 10.74万
  • 项目类别:
Requirements and mechanisms of alloantigen-induced cardiac allograft survival by cDC1s
cDC1同种异体抗原诱导心脏同种异体移植物存活的要求和机制
  • 批准号:
    10534556
  • 财政年份:
    2022
  • 资助金额:
    $ 10.74万
  • 项目类别:
Selective induction of alloantigen-specific humoral tolerance by MHC-Fc fusion proteins
MHC-Fc 融合蛋白选择性诱导同种异体抗原特异性体液耐受
  • 批准号:
    10612453
  • 财政年份:
    2022
  • 资助金额:
    $ 10.74万
  • 项目类别:
Preventing GVHD by inhibition of alloantigen presentation in the gut
通过抑制肠道内同种抗原的呈现来预防 GVHD
  • 批准号:
    10204102
  • 财政年份:
    2019
  • 资助金额:
    $ 10.74万
  • 项目类别:
Preventing GVHD by inhibition of alloantigen presentation in the gut
通过抑制肠道内同种抗原的呈现来预防 GVHD
  • 批准号:
    10443701
  • 财政年份:
    2019
  • 资助金额:
    $ 10.74万
  • 项目类别:
Preventing GVHD by inhibition of alloantigen presentation in the gut
通过抑制肠道内同种抗原的呈现来预防 GVHD
  • 批准号:
    10737340
  • 财政年份:
    2019
  • 资助金额:
    $ 10.74万
  • 项目类别:
Preventing GVHD by inhibition of alloantigen presentation in the gut
通过抑制肠道内同种抗原的呈现来预防 GVHD
  • 批准号:
    10652374
  • 财政年份:
    2019
  • 资助金额:
    $ 10.74万
  • 项目类别:
Generation of alloantigen-specific Designer Platelets for diagnostic and investigative use
生成用于诊断和研究用途的同种异体抗原特异性设计血小板
  • 批准号:
    9005358
  • 财政年份:
    2016
  • 资助金额:
    $ 10.74万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了